BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (2003) 76, 690-695
© 2003 British Institute of Radiology
doi: 10.1259/bjr/31538331
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, N
Right arrow Articles by Endo, K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, N
Right arrow Articles by Endo, K

Review article

PET in the follow-up of differentiated thyroid cancer

N Khan, MD, N Oriuchi, MD, T Higuchi, MD, H Zhang, DMSc and K Endo, MD

Department of Nuclear Medicine & Diagnostic Radiology, Gunma University, Faculty of Medicine, 3-39-22 Showamachi, Maebashi City, Gunma 371-8511, Japan

Fluorine-18-fluorodeoxyglucose (FDG) PET has become an increasingly important functional imaging modality in clinical oncology. This article will focus primarily on the role of FDG PET during treatment and follow-up of thyroid cancer. The major role of FDG PET is in patients with elevated thyroglobulin (Tg) levels where thyroid cancer tissue does not concentrate radioiodine rendering false-negative results on I-131 scanning. FDG PET imaging takes advantage of the increased uptake of FDG in cancer cells and is sensitive (60–94%) to the detection of recurrent or metastatic cancer in patients who have negative radioiodine scans. The specificity (25–90%) of PET imaging is relatively less than its sensitivity because some inflammatory processes avidly accumulate FDG. PET can fail to localize the tumour sites in some patients with well-differentiated thyroid cancer that retain good iodine ability. This can result the well recognized phenomenon of "flip-flop" depending on the differentiation of the thyroid cancer. Several studies have documented the higher accuracy of PET, compared with other imaging modalities in the evaluation of patients with recurrent or metastatic differentiated thyroid cancer. The value of thyroid stimulating hormone stimulation for FDG PET has recently been reported. Therefore, if available, this method should be considered in all patients of differentiated thyroid cancer with suspected recurrence and/or metastasis.




This article has been cited by other articles:


Home page
 RadiologyHome page
N. A. Johnson and M. E. Tublin
Postoperative Surveillance of Differentiated Thyroid Carcinoma: Rationale, Techniques, and Controversies
Radiology, November 1, 2008; 249(2): 429 - 444.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. T. Kloos
Approach to the Patient with a Positive Serum Thyroglobulin and a Negative Radioiodine Scan after Initial Therapy for Differentiated Thyroid Cancer
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1519 - 1525.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
J. D. Berry and G. J. R. Cook
Positron emission tomography in oncology
Br. Med. Bull., December 14, 2006; (2006) ldl013v1.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
M. B. Fukui, T. M. Blodgett, C. H. Snyderman, J. J. Johnson, E. N. Myers, D. W. Townsend, and C. C. Meltzer
Combined PET-CT in the Head and Neck: Part 2. Diagnostic Uses and Pitfalls of Oncologic Imaging
RadioGraphics, July 1, 2005; 25(4): 913 - 930.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2003 by the British Institute of Radiology.